Tesamorelin vs ipamorelin
These two are often grouped as growth-hormone-related peptides, which obscures how different they are. Tesamorelin is a GHRH analogue with a US approval for a specific population. Ipamorelin acts at the ghrelin receptor and has no approval at all.
This is a comparison where the regulatory gap is wider than the mechanistic one, and it should drive how you read everything else.
- TesamorelinGHRH analogue
- IpamorelinGhrelin receptor agonist
- Tesamorelin statusFDA-approved, narrow indication
- Ipamorelin statusNot approved
Two different pathways
Tesamorelin engages the GHRH receptor — the same receptor the hypothalamic signal uses. Ipamorelin engages the ghrelin receptor, a separate route into pituitary signalling that is characterised as selective.
Both are discussed in relation to the body's own growth hormone output rather than as growth hormone itself, which is a genuine and often-missed distinction. Neither is somatropin.
Status is where they separate
| Tesamorelin | Ipamorelin | |
|---|---|---|
| Receptor | GHRH | Ghrelin |
| US approval | Approved (Egrifta) | None |
| Licensed indication | HIV-associated lipodystrophy | None |
| Compounding position | Branded product available | FDA category raising significant safety concerns |
| Sport | Prohibited | Prohibited |
The practical reading: one of these has a regulator-reviewed dossier for a defined population, and the other does not have an approval to reason from at all. That gap should carry more weight in your thinking than any mechanistic argument.
What that gap means for evidence
An approval is not a general endorsement, but it does mean something concrete: a regulator has reviewed trial data for a defined population and concluded the balance was favourable for that use. Tesamorelin has that for its licensed indication. Ipamorelin has nothing equivalent.
In practice this changes what can even be discussed. For tesamorelin there is a label describing adverse effects, contraindications and monitoring. For ipamorelin there is no such document, so any account of what to expect is assembled from smaller studies and clinical impression rather than read off a reviewed source.
That does not settle whether either is appropriate for you. It does mean the two claims are not the same kind of claim, and they should not be weighed as though they were.
Cost factors
No figures here. A branded approved product and an unapproved compound reach a patient through entirely different channels and are priced through different mechanisms. Coverage for either outside a licensed indication is uncommon and should be confirmed rather than assumed.
For a branded product, the relevant questions are formulary placement and prior authorisation. For an unapproved compound obtained through a clinic, the cost is usually a bundle of consultation, laboratory work and the preparation itself, and it is worth asking which of those recur and how often.
What to ask
Ask why this particular compound, what is being measured before and after, what the source is, and what the plan is if nothing changes. Vague answers to any of those are informative in themselves.
If a clinic proposes ipamorelin specifically, it is entirely reasonable to ask how they obtain it given its compounding position, and what testing the preparation has been through. A provider working properly will treat that as a fair question rather than an awkward one.
Dosing is determined by a licensed provider.
Questions
Tesamorelin vs ipamorelin: common questions
- Is either of these growth hormone?
- Neither is. Both are discussed in relation to the body's own growth hormone signalling rather than being growth hormone itself.
- Is ipamorelin available on prescription?
- It has no US approval, and the FDA has placed it in the category of bulk substances raising significant safety concerns for compounding, which constrains lawful preparation.
- Can tesamorelin be prescribed for other goals?
- Clinicians can prescribe outside a licensed indication, but that is an explicit decision and the approval evidence does not automatically transfer to a different population.
- Are both prohibited in sport?
- Yes, both fall within the WADA prohibited list for this class.
Talk to a licensed provider
Anything in this category belongs in a conversation with a clinician who will investigate first and prescribe second. We connect you with licensed providers who work that way.
Find a licensed providerMedical disclaimer
TreatRadar is an information and referral service. We are not a medical provider, we do not practise medicine, and nothing here is medical advice, diagnosis, or a treatment recommendation. Decisions about treatment belong to you and a licensed clinician who knows your history.
We may be compensated when you connect with a provider through this site. That never changes which providers we list or how we describe them — how we verify providers.
Some information (pricing, provider coverage, state rules) may change or await verification — confirm details directly with the provider or the relevant state medical board before booking.